Global Influenza Drug Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 960.55 Billion |
 Market Size (Forecast Year) |
USD 1,084.07 Billion |
 CAGR |
% |
| Major Markets Players |
|
>全球流感药物市场，按类型（甲型流感、乙型流感和丙型流感）、治疗方法（疫苗和药物）、给药途径（口服、肌肉注射、皮内注射、鼻内注射和静脉注射）、年龄（儿科和成人）、最终用户（医院和家庭护理）、分销渠道（直接招标和零售销售）划分 - 行业趋势和预测到 2031 年。
流感药物市场分析及规模
全球流感药物市场的一个驱动因素是人们对流感及其潜在并发症的认识不断提高，这推动了对预防和治疗解决方案的需求增加。然而，一个显著的挑战是流感药物的仿制药的存在，导致价格压力和制造商利润率的潜在缩水。尽管如此，开发新型和更有效的药物来对抗新出现的流感病毒株仍是一个机会，可以提供竞争优势。然而，一个持续的挑战是需要不断进行研究和开发，以适应流感病毒不断发展的特性及其对当前治疗产生耐药性的趋势。
Data Bridge Market Research分析，全球流感药物市场在2024年至2031年的预测期内以6.5%的复合年增长率增长，预计将从2023年的87.3亿美元增至2031年的142.2亿美元。各类癌症患病率的上升预计将推动市场扩张。
|
报告指标 |
细节 |
|
预测期 |
2024 至 2031 年 |
|
基准年 |
2023 |
|
历史岁月 |
2022（可定制 2015-2020） |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
类型（甲型流感、乙型流感和丙型流感）、治疗（疫苗、药物）、给药途径（口服、肌肉注射、皮内注射、鼻内注射和静脉注射）、年龄（儿童和成人）、最终用户（医院和家庭护理）、分销渠道（直接招标和零售销售） |
|
覆盖国家 |
美国、加拿大、墨西哥、德国、意大利、英国、法国、瑞士、西班牙、俄罗斯、土耳其、比利时、荷兰、欧洲其他地区、中国、印度、韩国、日本、泰国、澳大利亚、新加坡、印度尼西亚、马来西亚、菲律宾、亚太其他地区、巴西、阿根廷、南美洲其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列以及中东和非洲其他地区 |
|
涵盖的市场参与者 |
GSK plc.、Sanofi SA、CSL、Astrazeneca Plc、F. Hoffmann-La Roche Ltd、Viatris Inc.、Abbott、Amneal Pharmaceuticals LLC.、AbbVie Inc BioCryst Pharmaceutucals, Inc.、Lupin、Zydus Pharmaceuticals, Inc.、Macleods Pharmaceuticals Ltd.、Viatris Inc.、DAIICHI SANKYO COMPANY, LIMITED、Cipla Inc.、Shionogi & Co., Ltd.、Teva Pharmaceutical Industries Ltd.、Takeda Pharmaceutical Company Limited、NATCO Pharma Limited 和 Alvogen 等 |
市场定义
流感药物是用于预防或治疗流感（一种传染性呼吸道疾病）的药物。它们包括针对流感病毒本身的抗病毒药物，以及有助于缓解发烧、咳嗽和鼻塞等症状的药物。这些药物对于控制和减轻流感爆发的影响至关重要，特别是在流感大规模传播或大流行期间。
全球流感药物市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。以下内容将详细讨论所有这些内容：
驱动程序
- 流感患病率上升
由于全球病毒感染的流行率不断上升，全球流感药物市场正在经历显著的增长。流感的流行率继续凸显出对流感药物和疫苗进步的迫切需求。随着各种毒株的出现和季节性爆发的持续威胁，流感药物市场经历了显著的增长。这种扩张的主要贡献者之一是开发和采用具有不同价数配方的疫苗。例如，四价疫苗可预防四种不同的流感毒株，与三价疫苗相比，覆盖范围更广。这些疫苗有多种形式，包括注射剂和鼻喷剂，可满足不同的偏好和需求。四价注射剂提供了一种方便有效的免疫方法，特别是对于寻求快速可靠的流感保护的个人。另一方面，鼻喷剂配方提供了一种替代选择，特别是对于那些不喜欢针头的人。此外，三价疫苗在特定病毒株流行的地区仍然必不可少，可确保针对性地预防流感病毒。通过整合包括四价和三价在内的多种价位选择，流感药物和疫苗市场不断发展，为抗击疾病传播和减轻其对公众健康的影响提供了全面的解决方案。
例如，
- 2023 年 10 月，根据世卫组织发表的文章，季节性流感给全球带来了巨大的健康负担，每年报告的病例约为 10 亿例，其中包括 300 万至 500 万例重症病例。这种影响在发展中国家尤为严重，5 岁以下儿童死亡病例中有 99% 是因流感相关的下呼吸道感染导致的，每年因此死亡的人数在 29 万至 65 万人之间，这凸显了该疾病的严重性及其潜在后果，尤其是在脆弱人群中
- 2021 年 11 月，根据 NCBI 发布的文章，流感疫情对公共卫生构成重大威胁，每年导致全球 29 万至 65 万人死亡。然而，流感大流行的损失可能更加惨重。1918-1919 年的甲型 H1N1 流感大流行，也称为西班牙流感，清楚地提醒人们流感爆发的潜在严重性。这场大流行导致全球约 2000 万至 5000 万人死亡，成为历史上最致命的大流行之一
总之，开发和利用多价流感药物和疫苗（例如四价制剂和鼻腔喷雾剂等替代给药方法）是有效控制流感流行的关键步骤。这种多管齐下的方法不仅可以提高疫苗接种覆盖率，而且还可以显著促进流感药物和疫苗市场的增长。因此，随着全球医疗保健行业继续将健康放在首位，病毒感染的日益流行成为治疗方式进步的催化剂，有助于全球流感市场的持续增长。
- 政府举措和疫苗接种计划
政府举措的增多和疫苗接种计划的扩大通过促进刺激需求在推动流感药物市场增长方面发挥着关键作用。随着世界各国政府通过全面的免疫战略将公共卫生放在首位，专门从事流感药物的制药公司将受益匪浅。通过积极参与政府举措，这些公司获得了为国家免疫计划供应疫苗的丰厚合同和采购机会。此外，参与疫苗接种计划使制药公司能够展示其流感药物的功效和安全性，从而提高其声誉和市场知名度。随着各国政府越来越重视对季节性流感爆发和潜在大流行的准备，对创新疫苗和疗法的需求持续上升。积极与政府机构合作、提供可靠的供应链并表现出对公共卫生目标承诺的公司将利用这一不断增长的市场需求。通过利用政府伙伴关系并积极参与疫苗接种计划，制药公司不仅可以为全球抗击流感做出贡献，还可以推动流感药物市场的可持续增长和扩张。各国政府也注重开展宣传活动，强调接种疫苗和遵守规定治疗方案的重要性，进一步推动市场的增长。
例如，
- 2023 年 12 月，根据美国疾病控制与预防中心发表的文章，美国政府将启动全国流感疫苗接种周 (NIVW)，这是每年 12 月举行的纪念活动，旨在提醒 6 个月及以上的所有人仍有时间接种流感疫苗。这项每年 12 月举行的活动旨在提高人们对流感疫苗接种重要性的认识，并鼓励更多人，特别是高危人群接种疫苗。NIVW 还为医疗保健提供者提供资源和工具，以促进全国的疫苗接种工作。
- 2023年7月，据澳大利亚卫生和老年护理部发表的文章称，澳大利亚政府启动了国家免疫计划（NIP），以增强符合条件的人群获得流感疫苗的机会。该计划向弱势群体免费提供流感疫苗，包括6个月至5岁以下的儿童、孕妇、原住民和托雷斯海峡岛民以及65岁及以上的个人。这一举措旨在减轻流感及其相关并发症对公共卫生的负担。
- 2024年3月，根据印度卫生和家庭福利部发表的文章，印度于1985年启动的全民免疫计划（UIP）（正在进行中）旨在为全国所有儿童接种可预防疾病的疫苗。近年来，印度扩大了免疫工作，为高危人群接种流感疫苗，例如医护人员、老年人和患有基础疾病的人。这些疫苗通常有三价和四价两种配方，含有抗病毒成分，有助于预防各种流感病毒株，包括乙型流感病毒。通过将这些疫苗纳入UIP，印度旨在减轻流感相关疾病的负担，为全国公共卫生状况的全面改善做出贡献。
总之，越来越多地参与各种政府举措和疫苗接种计划，大大促进了专门从事流感药物的制药公司的整体收入增长。通过与政府优先事项保持一致并积极参与免疫战略，这些公司获得了利润丰厚的合同和采购机会，从而推动了对其产品的需求。此外，参与疫苗接种计划使制药公司能够证明其流感药物的有效性和安全性，提高其声誉和市场知名度，从而吸引全球更多客户，并有望成为市场增长的驱动力
机会
- 远程医疗与数字健康解决方案的整合
远程医疗使医疗服务提供者能够远程咨询患者，及时评估和管理流感症状，而无需面对面就诊。这在流感爆发期间尤其有益，因为它降低了医疗环境中病毒传播的风险并改善了患者流量管理。
移动应用程序和可穿戴设备等数字健康解决方案对于监测流感症状和确保治疗依从性至关重要。这些工具允许患者跟踪他们的症状、用药时间表和整体健康状况，为医疗服务提供者的远程监控提供宝贵的数据。此外，这些数字工具使患者能够在医疗保健中发挥更积极的作用，从而改善治疗效果。
例如，
- 2022 年 4 月，根据 BioMed Central Ltd 发表的一篇文章，在对一名流感样疾病患者进行远程医疗就诊时，已确定检测阈值约为 25%，治疗阈值约为 60%。纳入家庭流感检测结果降低了不确定性，并显著减少了亲自就诊的必要性。
- 2022 年 2 月，根据 MDPI 发表的一篇文章，孕妇接种流感疫苗可减少孕妇患病和死亡，并降低婴儿的风险。一项关于“流感疫苗接种提醒应用程序”的研究发现，它提高了孕妇的知识、态度和接种疫苗的意愿。该应用程序可通过智能手机访问，提供有价值的信息，促进接种疫苗并防止错失机会。
- 2021 年 9 月，据强生服务公司发表的一篇文章称，Cue Health 是一个数字化连接的健康监测系统，从快速的居家诊断测试开始。该测试与远程医疗提供商相连，后者可以根据测试结果开药。Cue Health 最初专注于流感，是一家快速即时诊断公司。
- 2020 年 10 月，根据美国国立卫生研究院发表的一篇文章，奥司他韦可以缩短流感症状的持续时间，但必须在症状出现后 48 小时内给药。然而，在初级保健环境中，只有 20% 的患者接受了奥司他韦治疗。这一低比率通常是由于假阴性检测结果和患者在 48 小时窗口期后寻求治疗。直接面向消费者 (DTC) 的远程医疗可以通过全天 24 小时将患者与医生联系起来来解决这些挑战。这种方法可以帮助克服治疗延误并避免其他人受到感染。
总之，远程医疗和数字医疗在流感诊断和治疗中的整合提高了医疗保健的可及性，提高了患者的便利性，并实现了更加个性化和及时的护理。这种整合还为药物递送和监测创造了新的机会，使远程监测患者的健康状况成为可能，并促进向偏远或服务不足的地区递送抗病毒药物。总体而言，这种整合为推进流感和其他传染病管理中的医疗保健服务提供了重要机会。
克制/挑战
- 抗流感药物的副作用
尽管流感药物在控制流感感染方面有效，但由于可能出现不良副作用，因此可能会成为市场增长的制约因素。虽然恶心、呕吐、头痛和腹泻等常见副作用一般可以忍受，但过敏反应、皮疹或呼吸窘迫等更严重的反应可能会阻止患者继续使用。与抗病毒药物如奥司他韦 (Tamiflu) 和扎那米韦 (Relenza) 相关的神经精神事件（如幻觉或异常行为）的罕见发生，尤其是在年轻患者中，引起了医疗保健提供者和患者的担忧。这些不良反应可能会导致人们在开具或使用流感药物时犹豫不决，从而影响市场需求和增长。
例如，
- 2020 年 2 月，根据 NCBI 发布的文章，神经氨酸酶抑制剂 (NAI) 的不良反应表现出与年龄相关的差异，正如 WebMD 报告的研究结果所观察到的那样。在服用奥司他韦的年轻患者中，检测到呕吐和幻觉等不良反应的比例不成比例。相反，接受帕拉米韦治疗的老年患者表现出肝功能异常、心力衰竭、休克和心脏骤停等不良事件。精神疾病在年轻和年长年龄组中最为普遍，而服用奥司他韦的成年人中胃肠道疾病占主导地位
- 2024 年 4 月，根据梅奥医学教育与研究基金会 (MFMER) 发表的文章，恶心、眼睑或眼睛、面部、嘴唇或舌头周围浮肿或肿胀、严重头痛、皮疹、颈部和/或背部僵硬以及手臂和腿部突然麻木和无力等症状可能与某些用于治疗流感的药物和补充剂的严重不良反应有关。虽然奥司他韦 (Tamiflu) 和扎那米韦 (Relenza) 等流感药物通常耐受性良好，但在极少数情况下，个人可能会出现严重的过敏反应或不良反应。
总之，虽然流感药物在控制流感感染方面有效，但不良副作用的发生严重制约了市场的增长。恶心、呕吐和头痛等常见副作用，以及过敏反应和神经精神事件等更严重的反应，可能会阻止患者使用这些药物。对安全性和耐受性的担忧可能会导致医疗保健提供者在开具流感药物时犹豫不决，并降低患者对治疗方案的依从性。
最新动态
- 2023 年 11 月，阿斯利康宣布与临床阶段生物技术公司 Cellectis 达成合作和投资协议，以加快在肿瘤学、免疫学和罕见疾病等存在重大未满足医疗需求的领域开发新疗法。此次合作将使阿斯利康能够利用 Cellectis 的基因编辑技术和制造能力来创造创新的细胞和基因治疗产品，从而增强阿斯利康在该领域的产品组合。
- 2023 年 6 月，GSK plc. 和 BELLUS Health Inc. 今天宣布，GSK 已完成对 BELLUS 的收购，BELLUS 是一家致力于改善难治性慢性咳嗽 (RCC) 患者生活的生物制药公司。此次收购将通过增加 BELLUS 在难治性慢性咳嗽 (RCC) 治疗方面的专业知识来增强 GSK 的产品组合，加强其在解决该领域未满足的医疗需求方面的地位。
- 2023 年 6 月，赛诺菲举办了一场疫苗投资者活动，重点介绍了其产品线，展示了其战略如何得到疫苗研发的支持。该公司旨在通过流感、脑膜炎和儿科疫苗的核心特许经营权以及一流的呼吸道合胞病毒特许经营权来实现疫苗业务的持续增长，以保护婴儿、幼儿和老年人。此次活动将有助于赛诺菲强调其对疫苗研发和核心特许经营权的战略重点，展示其疫苗业务持续增长的潜力。
- 2022 年 11 月，CSL 宣布其子公司 CSL Seqirus 与 Arcturus Therapeutics Holdings Inc 签署了合作和许可协议，以在后期开发阶段利用其先进的自扩增 mRNA (sa-mRNA) 疫苗平台技术。此次合作将使 CSL Seqirus 能够利用 Arcturus Therapeutics 先进的 sa-mRNA 疫苗平台技术，从而有可能增强 CSL 的疫苗开发能力。
- 2022 年 5 月，葛兰素史克公司宣布达成最终协议，收购临床阶段生物制药公司 Affinivax, Inc.。此次收购涉及 21 亿美元的预付款和高达 12 亿美元的潜在开发里程碑。此次收购将通过整合 Affinivax 的创新 MAPS 技术来加强葛兰素史克的疫苗产品线，增强其开发针对各种传染病的下一代疫苗的能力。
- 2022 年 1 月，Natco Pharma Limited 最近宣布与瑞士药品专利池 (MPP) 签署非独家许可协议。MPP 此前已从美国默沙东公司 (MSD) 获得了相同目的的许可。与药品专利池达成的这项协议将使 Natco Pharma Limited 能够扩大其获得重要药品的渠道，并增强其向更广泛人群提供负担得起的医疗保健解决方案的能力。
- 2022 年 1 月，NATCO Pharma Limited 的全资子公司 NATCO Pharma Inc. USA 已完成对位于新泽西州的 Dash Pharmaceuticals LLC 的收购。此次交易完成后，Dash 将作为 NATCO Pharma Inc. 的全资子公司和 NATCO 的子公司运营。
全球流感药物市场范围
全球流感药物市场根据类型、治疗、给药途径、年龄、最终用户和分销渠道分为六个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
类型
- 甲型流感
- 乙型流感
- 丙型流感
根据类型，市场分为甲型流感、乙型流感和丙型流感。
治疗
- 疫苗
- 药物
根据治疗方法，市场分为疫苗和药物。
给药途径
- 口服
- 肌肉注射
- 皮内
- 鼻腔内
- 静脉
根据给药途径，市场分为口服、肌肉注射、皮内注射、鼻内注射和静脉注射。
年龄
- 儿科
- 成年人
根据年龄，市场分为儿科和成人。
最终用户
- 医院
- 家庭护理
根据最终用户，市场分为医院和家庭护理。
分销渠道
- 直接招标
- 零售销售
根据分销渠道，市场分为直接招标和零售。
全球流感药物市场区域分析/见解
对全球流感药物市场进行分析，并根据上述类型、治疗、给药途径、年龄、最终用户和分销渠道提供市场规模洞察和趋势。
本市场报告涵盖的国家包括美国、加拿大、墨西哥、德国、法国、英国、德国、西班牙、意大利、法国、俄罗斯、荷兰、土耳其、瑞士、比利时、欧洲其他地区、中国、日本、印度、韩国、澳大利亚、新加坡、泰国、印度尼西亚、菲律宾、马来西亚、亚太其他地区、巴西、阿根廷、南美洲其他地区、南非、沙特阿拉伯、阿联酋、埃及、以色列以及中东和非洲其他地区。
北美预计将占据市场主导地位，因为它拥有先进的医疗保健基础设施、设备齐全的医院、诊所和家庭护理中心，可确保为患者提供高质量的护理。
美国流感发病率高、医疗基础设施强大、制药业发达、民众流感预防意识强，有望在北美市场占据主导地位。英国医疗体系先进、疫苗接种覆盖率高、政府积极应对流感疫情，有望在欧洲市场占据主导地位。日本医疗水平高、研发能力先进、老年人口众多且特别容易感染流感，有望在亚太市场占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和全球流感药物市场份额分析
全球流感药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对全球流感药物市场的关注有关。
全球流感药物市场的一些主要参与者包括葛兰素史克公司 (GSK plc.)、赛诺菲公司 (Sanofi SA)、CSL、阿斯利康公司 (Astrazeneca Plc)、罗氏公司 (F. Hoffmann-La Roche Ltd)、Viatris Inc.、雅培 (Abbott)、Amneal Pharmaceuticals LLC.、艾伯维 (AbbVie Inc)、BioCryst Pharmaceutucals, Inc.、Lupin、Zydus Pharmaceuticals, Inc.、Macleods Pharmaceuticals Ltd.、Viatris Inc.、第一三共 (DAIICHI SANKYO COMPANY, LIMITED)、西普拉 (Cipla Inc.)、盐野义制药 (Shionogi & Co., Ltd.)、梯瓦制药工业有限公司 (Teva Pharmaceutical Industries Ltd.)、武田制药 (Takeda Pharmaceutical Company Limited)、NATCO Pharma Limited 和 Alvogen 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL INFLUENZA DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE RATE OF INFLUENZA
5.1.2 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
5.1.3 ADVANCEMENTS IN MEDICAL RESEARCH AND TECHNOLOGY
5.1.4 CONTINOUS LAUNCHES OF THE NEW DRUGS AND VACCINE
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECT OF ANTI-INFLUENZA DRUGS
5.2.2 COUNTERFEIT OF DRUG IN PHARMACEUTICAL INDUSTRY
5.3 OPPORTUNITIES
5.3.1 INTEGRATION OF TELEMEDICINE AND DIGITAL HEALTH SOLUTIONS
5.3.2 DEVELOPMENT OF COMBINATION THERAPIES
5.3.3 ADVANCING UNIVERSAL VACCINES
5.4 CHALLENGES
5.4.1 EMERGENCE OF DRUG RESISTANT STRAINS
5.4.2 INEFFICIENCY IN THE SUPPLY CHAIN OF VACCINE
6 GLOBAL INFLUENZA DRUG MARKET, BY TYPE
6.1 OVERVIEW
6.2 INFLUENZA A
6.3 INFLUENZA B
6.4 INFLUENZA C
7 GLOBAL INFLUENZA DRUG MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 VACCINES
7.3 DRUGS
8 GLOBAL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.3 INTRAMUSCULAR
8.4 INTRADERMAL
8.5 INTRANASAL
8.6 INTRAVENOUS
9 GLOBAL INFLUENZA DRUG MARKET, BY AGE
9.1 OVERVIEW
9.2 PEDIATRICS
9.3 ADULTS
10 GLOBAL INFLUENZA DRUG MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 HOMECARE
11 GLOBAL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
12 GLOBAL INFLUENZA DRUG MARKET, BY REGION
12.1 OVERVIEW
12.2 NORTH AMERICA
12.2.1 U S
12.2.2 MEXICO
12.2.3 CANADA
12.3 EUROPE
12.3.1 U.K.
12.3.2 GERMANY
12.3.3 SPAIN
12.3.4 ITALY
12.3.5 FRANCE
12.3.6 RUSSIA
12.3.7 NETHERLAND
12.3.8 TURKEY
12.3.9 SWITZERLAND
12.3.10 BELGIUM
12.3.11 REST OF EUROPE
12.4 ASIA-PACIFIC
12.4.1 JAPAN
12.4.2 CHINA
12.4.3 SOUTH KOREA
12.4.4 INDIA
12.4.5 AUSTRALIA
12.4.6 MALAYSIA
12.4.7 THAILAND
12.4.8 INDONESIA
12.4.9 SINGAPORE
12.4.10 PHILIPPINES
12.4.11 REST OF ASIA-PACIFIC
12.5 SOUTH AMERICA
12.5.1 BRAZIL
12.5.2 ARGENTINA
12.5.3 REST OF SOUTH AMERICA
12.6 MIDDLE EAST AND AFRICA
12.6.1 SOUTH AFRICA
12.6.2 U.A.E.
12.6.3 SAUDI ARABIA
12.6.4 EGYPT
12.6.5 ISRAEL
12.6.6 REST OF MIDDLE EAST AND AFRICA
13 GLOBAL INFLUENZA DRUG MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3 COMPANY SHARE ANALYSIS: EUROPE
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 GSK PLC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 SANOFI
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 CSL
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 ASTRAZENECA
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 F. HOFFMANN-LA ROCHE LTD.
15.5.1 COMPANY SNAPSHOT
15.5.1 REVENUE ANALYSIS
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 ABBVIE INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ALVOGEN
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 AMNEAL PHARMACEUTICALS LLC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 BIOCRYST PHARMACEUTICALS, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 CIPLA INC.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 DAIICHI SANKYO COMPANY, LIMITED
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LUPIN
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.14 MACLEODS PHARMACEUTICALS LTD.
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 NATCO PHARMA LIMITED
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 SHIONOGI & CO., LTD.
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 TAKEDA PHARMACEUTICAL COMPANY LIMITED
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 TEVA PHARMACEUTICAL INDUSTRIES LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENT
15.19 VIATRIS INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.2 ZYDUS PHARMACEUTICALS, INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 GLOBAL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 GLOBAL INFLUENZA A IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 GLOBAL INFLUENZA B IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 GLOBAL INFLUENZA C IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 GLOBAL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 6 GLOBAL INFLUENZA A IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 GLOBAL DRUGS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 GLOBAL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 9 GLOBAL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 10 GLOBAL TRIVALENTIN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 11 GLOBAL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 12 GLOBAL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 13 GLOBAL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 14 GLOBAL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 15 GLOBAL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 16 GLOBAL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 17 GLOBAL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 GLOBAL ORAL MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 GLOBAL INTRAMUSCULAR IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 GLOBAL INTRADERMAL IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 GLOBAL INTRANASAL IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 GLOBAL INTRAVENOUS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 GLOBAL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 24 GLOBAL PEDIATRICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 25 GLOBAL ADULTS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 GLOBAL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 27 GLOBAL HOSPITALS IN GLOBAL INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 GLOBAL HOMECARE IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 29 GLOBAL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 30 GLOBAL DIRECT TENDER IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 GLOBAL RETAIL SALES IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 GLOBAL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 33 GLOBAL INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 35 NORTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 37 NORTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 38 NORTH AMERICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 39 NORTH AMERICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 40 NORTH AMERICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 41 NORTH AMERICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 42 NORTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 43 NORTH AMERICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 44 NORTH AMERICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 45 NORTH AMERICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 46 NORTH AMERICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 47 NORTH AMERICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 48 NORTH AMERICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 51 U.S. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 U.S. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 53 U.S. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 54 U.S. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 55 U.S. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 56 U.S. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 57 U.S. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 58 U.S. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 59 U.S. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 60 U.S. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 61 U.S. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 62 U.S. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 63 U.S. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 64 U.S. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 65 U.S. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 66 U.S. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 67 MEXICO INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 MEXICO INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 69 MEXICO VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 70 MEXICO QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 71 MEXICO TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 72 MEXICO BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 73 MEXICO MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 74 MEXICO VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 75 MEXICO INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 76 MEXICO LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 77 MEXICO DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 78 MEXICO INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 79 MEXICO INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 80 MEXICO INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 81 MEXICO INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 82 MEXICO RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 83 CANADA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 CANADA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 85 CANADA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 86 CANADA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 87 CANADA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 88 CANADA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 89 CANADA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 90 CANADA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 91 CANADA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 92 CANADA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 93 CANADA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 94 CANADA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 95 CANADA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 96 CANADA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 97 CANADA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 98 CANADA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 99 EUROPE INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 100 EUROPE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 101 EUROPE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 102 EUROPE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 103 EUROPE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 104 EUROPE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 105 EUROPE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 106 EUROPE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 107 EUROPE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 108 EUROPE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 109 EUROPE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 110 EUROPE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 111 EUROPE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 112 EUROPE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 113 EUROPE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 114 EUROPE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 115 EUROPE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 116 U.K. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 U.K. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 118 U.K. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 119 U.K. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 120 U.K. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 121 U.K. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 122 U.K. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 123 U.K. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 124 U.K. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 125 U.K. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 126 U.K. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 127 U.K. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 128 U.K. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 129 U.K. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 130 U.K. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 131 U.K. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 132 GERMANY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 GERMANY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 134 GERMANY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 135 GERMANY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 136 GERMANY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 137 GERMANY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 138 GERMANY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 139 GERMANY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 140 GERMANY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 141 GERMANY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 142 GERMANY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 143 GERMANY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 144 GERMANY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 145 GERMANY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 146 GERMANY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 147 GERMANY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 148 SPAIN INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 SPAIN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 150 SPAIN VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 151 SPAIN QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 152 SPAIN TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 153 SPAIN BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 154 SPAIN MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 155 SPAIN VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 156 SPAIN INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 157 SPAIN LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 158 SPAIN DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 159 SPAIN INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 160 SPAIN INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 161 SPAIN INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 162 SPAIN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 163 SPAIN RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 164 ITALY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 ITALY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 166 ITALY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 167 ITALY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 168 ITALY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 169 ITALY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 170 ITALY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 171 ITALY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 172 ITALY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 173 ITALY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 174 ITALY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 175 ITALY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 176 ITALY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 177 ITALY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 178 ITALY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 179 ITALY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 180 FRANCE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 FRANCE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 182 FRANCE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 183 FRANCE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 184 FRANCE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 185 FRANCE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 186 FRANCE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 187 FRANCE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 188 FRANCE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 189 FRANCE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 190 FRANCE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 191 FRANCE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 192 FRANCE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 193 FRANCE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 194 FRANCE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 195 FRANCE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 196 RUSSIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 197 RUSSIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 198 RUSSIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 199 RUSSIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 200 RUSSIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 201 RUSSIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 202 RUSSIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 203 RUSSIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 204 RUSSIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 205 RUSSIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 206 RUSSIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 207 RUSSIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 208 RUSSIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 209 RUSSIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 210 RUSSIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 211 RUSSIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 212 NETHERLANDS INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 NETHERLANDS INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 214 NETHERLANDS VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 215 NETHERLANDS QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 216 NETHERLANDS TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 217 NETHERLANDS BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 218 NETHERLANDS MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 219 NETHERLANDS VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 220 NETHERLANDS INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 221 NETHERLANDS LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 222 NETHERLANDS DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 223 NETHERLANDS INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 224 NETHERLANDS INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 225 NETHERLANDS INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 226 NETHERLANDS INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 227 NETHERLANDS RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 228 TURKEY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 TURKEY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 230 TURKEY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 231 TURKEY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 232 TURKEY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 233 TURKEY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 234 TURKEY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 235 TURKEY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 236 TURKEY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 237 TURKEY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 238 TURKEY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 239 TURKEY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 240 TURKEY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 241 TURKEY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 242 TURKEY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 243 TURKEY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 244 SWITZERLAND INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 245 SWITZERLAND INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 246 SWITZERLAND VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 247 SWITZERLAND QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 248 SWITZERLAND TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 249 SWITZERLAND BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 250 SWITZERLAND MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 251 SWITZERLAND VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 252 SWITZERLAND INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 253 SWITZERLAND LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 254 SWITZERLAND DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 255 SWITZERLAND INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 256 SWITZERLAND INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 257 SWITZERLAND INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 258 SWITZERLAND INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 259 SWITZERLAND RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 260 BELGIUM INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 BELGIUM INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 262 BELGIUM VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 263 BELGIUM QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 264 BELGIUM TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 265 BELGIUM BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 266 BELGIUM MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 267 BELGIUM VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 268 BELGIUM INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 269 BELGIUM LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 270 BELGIUM DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 271 BELGIUM INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 272 BELGIUM INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 273 BELGIUM INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 274 BELGIUM INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 275 BELGIUM RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 276 REST OF EUROPE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 278 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 280 ASIA-PACIFIC VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 281 ASIA-PACIFIC QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 282 ASIA-PACIFIC TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 283 ASIA-PACIFIC BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 284 ASIA-PACIFIC MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 285 ASIA-PACIFIC VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 286 ASIA-PACIFIC INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 287 ASIA-PACIFIC LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 288 ASIA-PACIFIC DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 289 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 290 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 291 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 292 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 293 ASIA-PACIFIC RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 294 JAPAN INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 295 JAPAN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 296 JAPAN VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 297 JAPAN QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 298 JAPAN TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 299 JAPAN BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 300 JAPAN MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 301 JAPAN VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 302 JAPAN INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 303 JAPAN LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 304 JAPAN DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 305 JAPAN INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 306 JAPAN INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 307 JAPAN INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 308 JAPAN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 309 JAPAN RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 310 CHINA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 311 CHINA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 312 CHINA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 313 CHINA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 314 CHINA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 315 CHINA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 316 CHINA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 317 CHINA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 318 CHINA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 319 CHINA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 320 CHINA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 321 CHINA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 322 CHINA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 323 CHINA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 324 CHINA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 325 CHINA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 326 SOUTH KOREA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 327 SOUTH KOREA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 328 SOUTH KOREA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 329 SOUTH KOREA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 330 SOUTH KOREA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 331 SOUTH KOREA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 332 SOUTH KOREA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 333 SOUTH KOREA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 334 SOUTH KOREA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 335 SOUTH KOREA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 336 SOUTH KOREA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 337 SOUTH KOREA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 338 SOUTH KOREA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 339 SOUTH KOREA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 340 SOUTH KOREA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 341 SOUTH KOREA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 342 INDIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 343 INDIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 344 INDIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 345 INDIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 346 INDIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 347 INDIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 348 INDIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 349 INDIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 350 INDIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 351 INDIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 352 INDIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 353 INDIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 354 INDIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 355 INDIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 356 INDIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 357 INDIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 358 AUSTRALIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 AUSTRALIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 360 AUSTRALIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 361 AUSTRALIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 362 AUSTRALIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 363 AUSTRALIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 364 AUSTRALIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 365 AUSTRALIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 366 AUSTRALIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 367 AUSTRALIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 368 AUSTRALIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 369 AUSTRALIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 370 AUSTRALIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 371 AUSTRALIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 372 AUSTRALIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 373 AUSTRALIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 374 MALAYSIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 375 MALAYSIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 376 MALAYSIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 377 MALAYSIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 378 MALAYSIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 379 MALAYSIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 380 MALAYSIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 381 MALAYSIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 382 MALAYSIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 383 MALAYSIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 384 MALAYSIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 385 MALAYSIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 386 MALAYSIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 387 MALAYSIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 388 MALAYSIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 389 MALAYSIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 390 THAILAND INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 391 THAILAND INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 392 THAILAND VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 393 THAILAND QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 394 THAILAND TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 395 THAILAND BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 396 THAILAND MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 397 THAILAND VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 398 THAILAND INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 399 THAILAND LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 400 THAILAND DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 401 THAILAND INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 402 THAILAND INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 403 THAILAND INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 404 THAILAND INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 405 THAILAND RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 406 INDONESIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 407 INDONESIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 408 INDONESIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 409 INDONESIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 410 INDONESIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 411 INDONESIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 412 INDONESIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 413 INDONESIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 414 INDONESIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 415 INDONESIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 416 INDONESIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 417 INDONESIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 418 INDONESIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 419 INDONESIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 420 INDONESIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 421 INDONESIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 422 SINGAPORE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 423 SINGAPORE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 424 SINGAPORE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 425 SINGAPORE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 426 SINGAPORE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 427 SINGAPORE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 428 SINGAPORE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 429 SINGAPORE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 430 SINGAPORE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 431 SINGAPORE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 432 SINGAPORE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 433 SINGAPORE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 434 SINGAPORE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 435 SINGAPORE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 436 SINGAPORE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 437 SINGAPORE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 438 PHILIPPINES INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 439 PHILIPPINES INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 440 PHILIPPINES VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 441 PHILIPPINES QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 442 PHILIPPINES TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 443 PHILIPPINES BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 444 PHILIPPINES MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 445 PHILIPPINES VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 446 PHILIPPINES INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 447 PHILIPPINES LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 448 PHILIPPINES DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 449 PHILIPPINES INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 450 PHILIPPINES INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 451 PHILIPPINES INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 452 PHILIPPINES INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 453 PHILIPPINES RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 454 REST OF ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 455 SOUTH AMERICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 456 SOUTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 457 SOUTH AMERICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 458 SOUTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 459 SOUTH AMERICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 460 SOUTH AMERICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 461 SOUTH AMERICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 462 SOUTH AMERICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 463 SOUTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 464 SOUTH AMERICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 465 SOUTH AMERICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 466 SOUTH AMERICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 467 SOUTH AMERICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 468 SOUTH AMERICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 469 SOUTH AMERICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 470 SOUTH AMERICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 471 SOUTH AMERICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 472 BRAZIL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 473 BRAZIL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 474 BRAZIL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 475 BRAZIL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 476 BRAZIL TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 477 BRAZIL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 478 BRAZIL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 479 BRAZIL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 480 BRAZIL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 481 BRAZIL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 482 BRAZIL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 483 BRAZIL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 484 BRAZIL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 485 BRAZIL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 486 BRAZIL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 487 BRAZIL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 488 ARGENTINA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 489 ARGENTINA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 490 ARGENTINA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 491 ARGENTINA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 492 ARGENTINA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 493 ARGENTINA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 494 ARGENTINA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 495 ARGENTINA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 496 ARGENTINA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 497 ARGENTINA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 498 ARGENTINA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 499 ARGENTINA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 500 ARGENTINA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 501 ARGENTINA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 502 ARGENTINA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 503 ARGENTINA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 504 REST OF SOUTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 505 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 506 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 507 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 508 MIDDLE EAST AND AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 509 MIDDLE EAST AND AFRICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 510 MIDDLE EAST AND AFRICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 511 MIDDLE EAST AND AFRICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 512 MIDDLE EAST AND AFRICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 513 MIDDLE EAST AND AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 514 MIDDLE EAST AND AFRICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 515 MIDDLE EAST AND AFRICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 516 MIDDLE EAST AND AFRICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 517 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 518 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 519 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 520 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 521 MIDDLE EAST AND AFRICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 522 SOUTH AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 523 SOUTH AFRICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 524 SOUTH AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 525 SOUTH AFRICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 526 SOUTH AFRICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 527 SOUTH AFRICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 528 SOUTH AFRICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 529 SOUTH AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 530 SOUTH AFRICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 531 SOUTH AFRICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 532 SOUTH AFRICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 533 SOUTH AFRICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 534 SOUTH AFRICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 535 SOUTH AFRICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 536 SOUTH AFRICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 537 SOUTH AFRICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 538 U.A.E. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 539 U.A.E. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 540 U.A.E. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 541 U.A.E. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 542 U.A.E. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 543 U.A.E. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 544 U.A.E. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 545 U.A.E. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 546 U.A.E. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 547 U.A.E. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 548 U.A.E. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 549 U.A.E. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 550 U.A.E. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 551 U.A.E. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 552 U.A.E. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 553 U.A.E. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 554 SAUDI ARABIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 555 SAUDI ARABIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 556 SAUDI ARABIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 557 SAUDI ARABIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 558 SAUDI ARABIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 559 SAUDI ARABIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 560 SAUDI ARABIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 561 SAUDI ARABIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 562 SAUDI ARABIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 563 SAUDI ARABIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 564 SAUDI ARABIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 565 SAUDI ARABIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 566 SAUDI ARABIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 567 SAUDI ARABIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 568 SAUDI ARABIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 569 SAUDI ARABIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 570 EGYPT INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 571 EGYPT INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 572 EGYPT VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 573 EGYPT QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 574 EGYPT TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 575 EGYPT BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 576 EGYPT MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 577 EGYPT VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 578 EGYPT INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 579 EGYPT LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 580 EGYPT DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 581 EGYPT INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 582 EGYPT INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 583 EGYPT INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 584 EGYPT INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 585 EGYPT RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 586 ISRAEL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 587 ISRAEL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 588 ISRAEL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 589 ISRAEL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 590 ISRAEL TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 591 ISRAEL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 592 ISRAEL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 593 ISRAEL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 594 ISRAEL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 595 ISRAEL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 596 ISRAEL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 597 ISRAEL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 598 ISRAEL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 599 ISRAEL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 600 ISRAEL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 601 ISRAEL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 602 REST OF MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
图片列表
FIGURE 1 GLOBAL INFLUENZA DRUG MARKET: SEGMENTATION
FIGURE 2 GLOBAL INFLUENZA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL INFLUENZA DRUG MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL INFLUENZA DRUG MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL INFLUENZA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL INFLUENZA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL INFLUENZA DRUG MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL INFLUENZA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL INFLUENZA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL INFLUENZA DRUG MARKET: SEGMENTATION
FIGURE 11 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS IS DRIVING THE GROWTH OF THE GLOBAL INFLUENZA DRUG MARKET FROM 2024 TO 2031
FIGURE 12 THE INFLUENZA A SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL INFLUENZA DRUG MARKET IN 2024 AND 2031
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL INFLUENZA DRUG MARKET AND ALSO NORTH AMERICA IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR INFLUENZA DRUG MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL INFLUENZA DRUGS MARKET
FIGURE 16 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, 2023
FIGURE 17 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 18 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 19 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL INFLUENZA DRUG MARKET: BY TREATMENT, 2023
FIGURE 21 GLOBAL INFLUENZA DRUG MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 22 GLOBAL INFLUENZA DRUG MARKET: BY CAGR (2024-2031)
FIGURE 23 GLOBAL INFLUENZA DRUG MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 24 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, 2023
FIGURE 25 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 26 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 27 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 GLOBAL INFLUENZA DRUG MARKET : BY AGE, 2023
FIGURE 29 GLOBAL INFLUENZA DRUG MARKET : BY AGE, 2024-2031 (USD THOUSAND)
FIGURE 30 GLOBAL INFLUENZA DRUG MARKET : BY AGE, CAGR (2024-2031)
FIGURE 31 GLOBAL INFLUENZA DRUG MARKET : BY AGE, LIFELINE CURVE
FIGURE 32 GLOBAL INFLUENZA DRUG MARKET : BY END USER, 2023
FIGURE 33 GLOBAL INFLUENZA DRUG MARKET : BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 34 GLOBAL INFLUENZA DRUG MARKET : BY END USER, CAGR (2024-2031)
FIGURE 35 GLOBAL INFLUENZA DRUG MARKET : BY END USER, LIFELINE CURVE
FIGURE 36 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 37 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 38 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 39 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 GLOBAL INFLUENZA DRUG MARKET: SNAPSHOT (2023)
FIGURE 41 GLOBAL INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
FIGURE 42 NORTH AMERICA INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
FIGURE 43 EUROPE INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
FIGURE 44 AISA-PACIFIC INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
